10.3.1
Presumptive DR-TB /risk groups
National TB Management Guidelines, 2018 Edition. Chapter 10, Programmatic and Clinical Management of Drug-Resistant TB.
Clinical description
According to the national drug resistance survey13, previously treated patients are 12 times more likely to have DR-TB than new patients. Presumptive DR-TB patients are defined as the following risk groups:
- All patients, who remain smear-positive after 3 months of therapy with first-line
drugs14;
- Patients who have had contact with a known DR-TB patient;
- Failure of first line TB drugs
- Symptomatic contacts of a DR-TB patient who died while on directly observed TB
treatment;
- New patients coming from areas with high prevalence of DR TB;
- Health care workers in hospital/ health facility setting;
- Other previously treated TB Patients;
- TB patients returning after loss to follow-up;
- Any TB patients in whom there is significant clinical concern for acquired resistance.
- Whenever health workers encounter presumptive MDR-TB cases
- Submit sputum for microscopy or Xpert MTB/RIF, culture /DST.
Patients are assigned to a registration group based on the most recent treatment history at the time of collecting the biological specimen that waså used to confirm MDR-TB or RR-TB. All confirmed drug-resistant TB patients should be treated as per the national guidelines.
13 Abouyannis et al. 2014. Drug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional survey. Bull WHO; 92:798-806.
http://www.who.int/bulletin/volumes/92/11/13-126532/en/ Accessed 7 April 2017.
14 WHO. WHO treatment guidelines for drug-resistant tuberculosis.2016 Updates. Accessed on June 13,2017.
National Tuberculosis Control Programme 69
Check doses against the printed guideline and your clinical judgement before treating a patient. Spotted an error? Report it from the contact links below.
Need this without data?
The app holds every guideline on your device, with calculators, bookmarks and notes.